Determine the necessary mass, volume, or concentration for preparing a solution.
≥98% 최소한의 기준선 간섭이 필요한 민감한 크로마토그래피 및 분석 워크플로우용.
Protected from light,Store at -80°C Dry ice packs + Cold packs 출고. 정확한 사양은 로트별 COA를 확인하세요.
SDS, COA, 데이터시트, 사양서를 다운로드할 수 있습니다. 로트별 COA는 로트 번호 조회를 통해 확인할 수 있습니다.
크로마토그래피, 유기 합성 및 교차 커플링 반응 분야의 동료 심사 논문 0편에서 인용되었습니다.
BSc3094 is a Tau aggregation inhibitor. BSc3094 can be used for the research of Alzheimer's disease (AD)
In Vivo
BSc3094 (3 mg/kg; i.v.) direct intraventricular administration reduces sarkosyl-insoluble Tau . BSc3094 (0.075~1.5 mM; intraventricular administration) reduces the levels of sarkosyl-insoluble Tau in cortical extracts by ≈70% . BSc3094 reverses the pre-synaptic impairment in organotypic hippocampal slices from pro-aggregant mice, by reversing the pairedpulse depression observed in non-treated pro-aggregant Tau slices after applying a paired-pulse stimulus of the Schaffer collaterals. BSc3094 reverses the increase in Tau phosphorylation levels in rTg4510 mice down to control level. BSc3094 partially reversed the memory deficits in rTg4510 mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Mice Dosage: 3 mg/kg Administration: I.v. Result: Direct intraventricular administration reduced sarkosyl-insoluble Tau. Animal Model: rTg4510 mice Dosage: 0.075~1.5 mM Administration: Intraventricular administration Result: Reduced the levels of sarkosyl-insoluble Tau in cortical extracts by ≈70%.
Form:Solid
IC50& Target:Tau aggregation
위험성, 취급, 보관 및 규제 준수를 포괄하는 종합 문서.
<<<<<<< HEAD SDS 다운로드 → ======= SDS 다운로드 → >>>>>>> release248-p3| 용해성 | DMSO : 33.33 mg/mL (87.62 mM; Need ultrasonic) |
|---|